Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Staar’s Visian TICL requires FDA panel review

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement for Staar Surgical's Visian TICL toric implantable Collamer lens for treating myopia and astigmatism will require review by the agency's Ophthalmic Devices Panel, contrary to the firm's expectations. As a result, FDA approval will now be "unlikely in 2007, as previously anticipated," Staar says Feb. 6. The panel is needed since Visian TICL is "the first toric phakic implantable lens to be reviewed," according to the company. The supplement, submitted last April, references a December 2005 PMA approval for Staar's Visian ICL for myopia. FDA had asked Staar to amend the Visian TICL supplement last November (1"The Gray Sheet" Dec. 4, 2006, In Brief)...

Related Content

Staar Surgical warning
FDA delays Staar toric submission



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts